Sponsored by
In their quarterly financial report, Novocure announced that the FDA granted Breakthrough Device designation for the use of Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer. The Breakthrough Device designation is a special status granted to innovative medical devices that have the potential to more effectively treat life-threatening or irreversibly debilitating conditions and allows for expedited development and review process so these devices can potentially reach patients faster.